Eton Pharmaceuticals, Inc. (ETON)
$52.88-0.84%Close
SELLRECOVERY · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.4B
- Beta
- 0.90
- P/E (TTM)
- 113.72
- Short % float
- 8.71%
- Days to cover
- 2.9
- SI change
- +18.9%
- 1W
- -3.64%
- 1M
- -3.73%
- vs SPY 1W
- -2.66%
- vs SPY 1M
- -5.60%
Industry peers
FMP comparable companies · ranked by market cap
- IONSSELLIonis Pharmaceuticals, Inc.$7.3BCRISISQ 8$44.16+0.76%
- TVTXSELLTravere Therapeutics, Inc.$5.0BCRISISQ 33$53.44+2.84%
- RAREBUYUltragenyx Pharmaceutical Inc.$1.5BRECOVERYQ -6$14.89-0.13%
- LXRXSELLLexicon Pharmaceuticals, Inc.$782MCRISISQ 5$1.76-0.62%
- PHARSELLPharming Group N.V.$683MCRISISQ -1$9.65+2.12%
- ZVRASELLZevra Therapeutics, Inc.$655MCRISISQ -8$11.08-1.54%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ETON?
- LOPJLB’s latest quantitative signal on Eton Pharmaceuticals, Inc. (ETON) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is ETON in?
- Eton Pharmaceuticals, Inc. (ETON) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Eton Pharmaceuticals, Inc. (ETON) do?
- Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid fo…